ArticleCancer gene therapy2026
SATB1 regulates TXNIP inhibiting invasion and infiltration in T-cell acute lymphoblastic leukemia.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis. Thioredoxin-interacting protein (TXNIP), a key protein, binds to thioredoxin and acts as a tumor suppressor in multiple cancers. However, its specific functions and mechanisms in T-ALL remain unclear. Here, CCK-8 and Transwell assays were used to assess its proliferation and invasiveness, with findings validated in a murine leukemia model. 4D proteomics combined with bioinformatics analyses were applied to elucidate its role in DNA damage repair. Guided by CHIP-seq results, we further validated the regulatory axis between Special AT-rich sequence binding protein 1 (SATB1) and TXNIP, as well as their involvement in T-ALL invasion, using CHIP-PCR and rescue assays. Our data demonstrated low expression of TXNIP in T-ALL patients. TXNIP significantly inhibited the proliferation and invasiveness of T-ALL cells and was involved in DNA damage response by suppressing MRN complex (MRE11-RAD50-NBS1) expression. We also identified SATB1 as a transcriptional regulator of TXNIP in Jurkat cells. Notably, TXNIP overexpression counteracted the pro-invasive effects induced by SATB1 knockdown in Jurkat cells (P < 0.05). In summary, TXNIP inhibits the proliferation and invasion of T-ALL, and impairs DNA damage repair processes. SATB1 positively regulates TXNIP, thereby suppressing the invasiveness of Jurkat cells.
Indexed as
Identifiers
41125904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.